Peter G. Mortimer
Impact in
- Oncology top 1%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 20
- PARP inhibition in cancer therapy 10
- Lung Cancer Research Studies 6
-
- Cancer therapeutics and mechanisms 7
- DNA Repair Mechanisms 4
- PI3K/AKT/mTOR signaling in cancer 4
- Co-authors
- Johann S. de Bono (3 shared papers)Helen Swaisland (1 shared paper)Alan Ashworth (1 shared paper)Peter C.C. Fong (2 shared papers)Jan H.M. Schellens (1 shared paper)Andrew Tutt (2 shared papers)Mark J. O’Connor (1 shared paper)James Carmichael (1 shared paper)
- Journals
- Journal of Clinical Oncology (13 papers)Cancer (3 papers)British Journal of Cancer (3 papers)Journal of Antimicrobial Chemotherapy (2 papers)Annals of Oncology (2 papers)
- Partner nations
- United KingdomSouth KoreaUnited States
In The Last Decade
Peter G. Mortimer
38 papers receiving 3.6k citations
Peter G. Mortimer's Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 2.2k
- Cancer Research 556
- Reproductive Medicine 265
- Molecular Medicine 154
- Molecular Biology 1.9k
Countries citing papers authored by Peter G. Mortimer
This map shows the geographic impact of Peter G. Mortimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. Mortimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. Mortimer more than expected).
Fields of papers citing papers by Peter G. Mortimer
This network shows the impact of papers produced by Peter G. Mortimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. Mortimer. The network helps show where Peter G. Mortimer may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter G. Mortimer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 2716 |
| 2 | 1991 | 159 | |
| 3 | 2021 | 86 | |
| 4 | 1993 | 85 | |
| 5 | 2007 | 77 | |
| 6 | 2021 | 63 | |
| 7 | 2022 | 63 | |
| 8 | 2021 | 60 | |
| 9 | 2008 | 45 | |
| 10 | 2009 | 33 | |
| 11 | 2020 | 29 | |
| 12 | 1981 | 29 | |
| 13 | 2021 | 24 | |
| 14 | 2009 | 21 | |
| 15 | 2023 | 19 | |
| 16 | 2020 | 19 | |
| 17 | 2021 | 14 | |
| 18 | 2012 | 14 | |
| 19 | 2023 | 13 | |
| 20 | 2009 | 13 |
About Peter G. Mortimer
Peter G. Mortimer is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 39 papers that have together received 3.7k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (10 papers), Cancer therapeutics and mechanisms (7 papers), Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers), Prostate Cancer Treatment and Research (5 papers), DNA Repair Mechanisms (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Oncology (2.2k citations), Cancer Research (556 citations), Reproductive Medicine (265 citations), Molecular Medicine (154 citations) and Molecular Biology (1.9k citations). Peter G. Mortimer has collaborated with scholars based in United Kingdom, South Korea and United States. Frequent co-authors include Johann S. de Bono, Helen Swaisland, Alan Ashworth, Peter C.C. Fong, Jan H.M. Schellens, Andrew Tutt, Mark J. O’Connor, James Carmichael, David S. Boss and Timothy A. Yap. Their work appears in journals such as Journal of Clinical Oncology, Cancer, British Journal of Cancer, Journal of Antimicrobial Chemotherapy and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.